Posts Tagged ‘semaglutide’

It is eye-popping really. Novo Nordisk issued a press release from the European Society of Cardiology (ESC) Congress over the weekend, with extravagant claims for Wegovy versus tirzepatide. Specifically, the claim was that “Wegovy cuts risk of heart attack, stroke or death by 57% compared to tirzepatide.” This is quite an amazing claim to make. […]

Researchers presented and published two major studies of heart disease outcomes at the ESC Congress of the European Society of Cardiology over the weekend with strikingly different findings. In the REBOOT study, scientists found that beta blockers have no effect on outcomes when given to patients after a heart attack. None. People might be better […]

By now, it should be obvious. List prices for GLP-1 medicines like semaglutide and tirzepatide are fiction. If you had any doubt, read up on the deal Novo Nordisk just struck with GoodRx to sell both the Ozempic and Wegovy brands of semaglutide for $499 per month. This deal with GoodRx is happening for two […]

Late yesterday FDA granted Wegovy (semaglutide 2.4 mg) a big new indication – treatment of MASH. The indication FDA approved reads as follows: “For the treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH), with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis) in adults. “The indication […]

YouGov released some fascinating new survey research on Friday that shows GLP-1 awareness rising sharply and a profound shift in views of obesity as this happens. Dramatic Growth in Awareness Two years ago, only 23% of U.S. adults knew “a lot” about semaglutide. Now, that number has grown to 41%. Total awareness is now up […]

Monday, Reuters reported that Novo Nordisk has been seeing a bump in prescription volume for Wegovy because FDA had ordered an end to the widespread sale of compounded semaglutide on May 22. New Wegovy prescriptions were up 33%, the report said. But they went on to say that investors were looking for more assurance of […]

It’s no secret that Novo Nordisk is in something of a funk. In the last year, the value of the company has dropped by half. Its respected leader, Lars Fruergaard Jørgensen, stepped down suddenly in May. Lilly has taken the lead in the obesity market from semaglutide with its own tirzepatide, and numerous competitors are […]

A new scientific statement from the American College of Cardiology (ACC) marks a milestone in acknowledging the importance of treating obesity in patients with heart failure. It seems that cardiologists see the light and are recognizing the importance of moving beyond diet and lifestyle advice alone. The statement concludes: “Given emerging evidence of the benefits […]

A new report from Reuters tells us that Novo Nordisk is having a hard time coming to terms with its failure to solidify a leadership position in the obesity market it created from nothing with semaglutide. Former executives and financial analysts alike say the company was too conservative and unprepared for a blockbuster launch: “way, way, […]

A dramatic race is progressing quietly and out of view for most of us. It is the race toward better therapy for the liver disease doctors know as MASH (metabolic associated steatohepatitis), which has close ties to obesity. And likewise because of advances in obesity science, progress in treating MASH is advancing with blinding speed […]